Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:DNLI NASDAQ:IBRX NASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$15.82+0.2%$15.94$9.60▼$19.09$2.13B1.47968,376 shs180,958 shsDNLIDenali Therapeutics$15.29+3.4%$14.52$10.57▼$33.33$2.25B1.231.47 million shs2.97 million shsIBRXImmunityBio$2.40+0.2%$2.57$1.83▼$7.48$2.27B0.37.83 million shs3.49 million shsTRMLTourmaline Bio$27.28+8.7%$20.55$11.56▼$29.79$693.12M2.04280,890 shs253,655 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals-0.75%-4.65%-8.78%+32.47%+7.93%DNLIDenali Therapeutics-3.40%-5.50%+3.50%+0.61%-41.22%IBRXImmunityBio+0.84%+2.58%-0.83%-24.13%-35.41%TRMLTourmaline Bio-0.04%+8.99%+11.95%+30.25%+53.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$15.82+0.2%$15.94$9.60▼$19.09$2.13B1.47968,376 shs180,958 shsDNLIDenali Therapeutics$15.29+3.4%$14.52$10.57▼$33.33$2.25B1.231.47 million shs2.97 million shsIBRXImmunityBio$2.40+0.2%$2.57$1.83▼$7.48$2.27B0.37.83 million shs3.49 million shsTRMLTourmaline Bio$27.28+8.7%$20.55$11.56▼$29.79$693.12M2.04280,890 shs253,655 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals-0.75%-4.65%-8.78%+32.47%+7.93%DNLIDenali Therapeutics-3.40%-5.50%+3.50%+0.61%-41.22%IBRXImmunityBio+0.84%+2.58%-0.83%-24.13%-35.41%TRMLTourmaline Bio-0.04%+8.99%+11.95%+30.25%+53.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 3.08Buy$31.4598.83% UpsideDNLIDenali Therapeutics 3.12Buy$33.62119.91% UpsideIBRXImmunityBio 3.20Buy$10.75348.85% UpsideTRMLTourmaline Bio 3.00Buy$50.1483.84% UpsideCurrent Analyst Ratings BreakdownLatest TRML, CNTA, DNLI, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025CNTACentessa PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025CNTACentessa PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$31.008/29/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$40.008/26/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/14/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/14/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.008/14/2025TRMLTourmaline BioGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.008/12/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/5/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.007/30/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$15M141.23N/AN/A$3.05 per share5.19DNLIDenali Therapeutics$330.53M6.76N/AN/A$8.53 per share1.79IBRXImmunityBio$56.60M40.00N/AN/A($0.57) per share-4.20TRMLTourmaline BioN/AN/AN/AN/A$11.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%11/11/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)TRMLTourmaline Bio-$73.21M-$3.43N/AN/AN/AN/A-30.50%-29.63%11/6/2025 (Estimated)Latest TRML, CNTA, DNLI, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025TRMLTourmaline Bio-$0.94-$0.90+$0.04-$0.90N/AN/A8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/5/2025Q2 2025IBRXImmunityBio-$0.10-$0.10N/A-$0.10$21.95 million$26.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.3210.1110.12DNLIDenali Therapeutics0.0110.2710.27IBRXImmunityBioN/A4.113.98TRMLTourmaline BioN/A24.6824.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%DNLIDenali Therapeutics92.92%IBRXImmunityBio8.58%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals7.09%DNLIDenali Therapeutics12.50%IBRXImmunityBio76.79%TRMLTourmaline Bio13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200133.91 million124.42 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableIBRXImmunityBio590945.26 million219.39 millionOptionableTRMLTourmaline Bio4425.69 million22.35 millionOptionableTRML, CNTA, DNLI, and IBRX HeadlinesRecent News About These CompaniesJump Financial LLC Makes New Investment in Tourmaline Bio, Inc. $TRMLSeptember 4 at 3:56 AM | marketbeat.comNuveen LLC Invests $1.18 Million in Tourmaline Bio, Inc. $TRMLSeptember 3 at 3:38 AM | marketbeat.comTourmaline Bio, Inc. $TRML is QVT Financial LP's 7th Largest PositionSeptember 2 at 9:40 AM | marketbeat.comVanguard Group Inc. Buys 84,685 Shares of Tourmaline Bio, Inc. $TRMLSeptember 1, 2025 | marketbeat.comTourmaline Bio highlights positive phase 2 pacibekitug dataSeptember 1, 2025 | msn.comTourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology CongressAugust 31, 2025 | globenewswire.comTourmaline Bio, Inc. $TRML Shares Bought by Velan Capital Investment Management LPAugust 31, 2025 | marketbeat.comEntryPoint Capital LLC Invests $380,000 in Tourmaline Bio, Inc. $TRMLAugust 23, 2025 | marketbeat.comAnalysts Set Expectations for Tourmaline Bio FY2025 EarningsAugust 19, 2025 | marketbeat.comTourmaline Bio Q3 EPS Forecast Raised by Leerink PartnrsAugust 19, 2025 | marketbeat.comLifesci Capital Expects Higher Earnings for Tourmaline BioAugust 19, 2025 | marketbeat.comWhat is Wedbush's Forecast for Tourmaline Bio Q3 Earnings?August 19, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPSAugust 17, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from Chardan CapitalAugust 16, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Receives Buy Rating from GuggenheimAugust 16, 2025 | marketbeat.comWall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should KnowAugust 15, 2025 | zacks.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by BrokeragesAugust 14, 2025 | marketbeat.comTourmaline Bio Reports Positive Trial Results and Strong Cash PositionAugust 13, 2025 | tipranks.comTourmaline Bio, Inc.: Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 13, 2025 | finanznachrichten.deTourmaline Bio reports Q2 EPS (90c), consensus (93c)August 13, 2025 | msn.comTourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRML, CNTA, DNLI, and IBRX Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$15.82 +0.03 (+0.19%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Denali Therapeutics NASDAQ:DNLI$15.29 +0.50 (+3.35%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.ImmunityBio NASDAQ:IBRX$2.40 +0.01 (+0.21%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Tourmaline Bio NASDAQ:TRML$27.28 +2.18 (+8.67%) As of 01:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
